827156--10/15/2007--ZILA_INC

related topics
{product, liability, claim}
{property, intellectual, protect}
{personnel, key, retain}
{condition, economic, financial}
{debt, indebtedness, cash}
{cost, operation, labor}
{customer, product, revenue}
{cost, contract, operation}
{stock, price, share}
Our lack of earnings history could adversely affect our financial health and prevent us from fulfilling our payment obligations, and if we are unable to generate funds or obtain funds on acceptable terms, we may not be able to develop and market our present and potential products. Our debt instruments contain restrictive covenants that could adversely affect our business by limiting our flexibility. We may fail to realize the anticipated cost savings, revenue enhancements, product focus, or other benefits expected from our recent acquisition of Pro-Dentec. Historically we have been dependent on a few key products and our future growth is dependent on the development and/or acquisition of new products. Our proprietary rights may prove difficult to enforce. We are dependent on our senior management and other key personnel. We and our products are subject to regulatory oversight that could substantially interfere with our ability to do business. We are at risk with respect to product liability claims. We face significant competition that could adversely affect our results of operation and financial condition. If the use of our technology is determined to infringe on the intellectual property rights of others, our business could be harmed. We require certain raw materials for our manufacturing processes that may only be acquired through limited sources. We have, in the past, received minor deficiencies from regulatory agencies related to our manufacturing facilities. Trends, Risks and Uncertainties Related to Our Capital Stock The Private Placements and other financing arrangements or corporate events could significantly dilute existing ownership.

Full 10-K form ▸

related documents
827156--10/6/2008--ZILA_INC
827156--10/10/2006--ZILA_INC
31791--2/28/2008--PERKINELMER_INC
739944--3/15/2007--MEDTOX_SCIENTIFIC_INC
768408--6/24/2010--CYANOTECH_CORP
739944--3/11/2008--MEDTOX_SCIENTIFIC_INC
739944--3/10/2009--MEDTOX_SCIENTIFIC_INC
739944--3/17/2006--MEDTOX_SCIENTIFIC_INC
1114200--2/27/2008--AMERICAN_MEDICAL_SYSTEMS_HOLDINGS_INC
780127--1/12/2007--SYNOVIS_LIFE_TECHNOLOGIES__INC
911649--4/2/2007--STRATEGIC_DIAGNOSTICS_INC/DE/
862668--9/29/2008--ESCALON_MEDICAL_CORP
10456--2/26/2008--BAXTER_INTERNATIONAL_INC
880432--9/28/2009--MISONIX_INC
1050007--11/30/2006--NUTRACEUTICAL_INTERNATIONAL_CORP
31791--2/26/2009--PERKINELMER_INC
1033905--3/16/2006--LUMINEX_CORP
912093--8/31/2010--JDS_UNIPHASE_CORP_/CA/
882873--9/21/2009--UROLOGIX_INC
1263074--3/14/2008--PORTEC_RAIL_PRODUCTS_INC
862668--10/12/2010--ESCALON_MEDICAL_CORP
1006195--3/15/2007--MATRIXX_INITIATIVES_INC
810084--4/2/2007--BIOJECT_MEDICAL_TECHNOLOGIES_INC
7536--2/8/2008--ARROW_ELECTRONICS_INC
874734--3/8/2010--OSTEOTECH_INC
874734--3/16/2009--OSTEOTECH_INC
874710--9/26/2008--ALLIED_HEALTHCARE_PRODUCTS_INC
874710--9/28/2007--ALLIED_HEALTHCARE_PRODUCTS_INC
31791--3/1/2010--PERKINELMER_INC
1005010--2/29/2008--ARTHROCARE_CORP